Literature DB >> 9207716

Epidemiology, pathogenesis, and treatment of the common cold.

R B Turner1.   

Abstract

OBJECTIVE: Reading this article will reinforce the reader's knowledge of the pathogenesis of the common cold. The rationale for current and potential therapies for the common cold are reviewed in the context of current concepts of the pathogenesis of these illnesses. DATA SOURCES AND STUDY SELECTION: A MEDLINE literature search was done using the search terms common cold, rhinovirus, and viral respiratory infection. The search was restricted to the English language. Articles were selected for review if the title and/or abstract suggested the content was relevant to the subject of this review. The bibliographies of selected articles were used as a source of additional literature.
RESULTS: Recent studies suggest that the host response to the virus is an important contributor to the pathogenesis of the common cold. Inflammatory mediators, especially the pro-inflammatory cytokines, appear to be an important component of this response and present an attractive target for new interventions for common cold therapies. Currently available treatments for the common cold have limited efficacy against specific symptoms. These therapies should be selected to treat the specific symptoms that are perceived to be the most bothersome by the patient.

Entities:  

Mesh:

Year:  1997        PMID: 9207716      PMCID: PMC7128171          DOI: 10.1016/S1081-1206(10)63213-9

Source DB:  PubMed          Journal:  Ann Allergy Asthma Immunol        ISSN: 1081-1206            Impact factor:   6.347


  119 in total

1.  Kinins are generated in nasal secretions during natural rhinovirus colds.

Authors:  D Proud; R M Naclerio; J M Gwaltney; J O Hendley
Journal:  J Infect Dis       Date:  1990-01       Impact factor: 5.226

2.  Nasal provocation with bradykinin induces symptoms of rhinitis and a sore throat.

Authors:  D Proud; C J Reynolds; S Lacapra; A Kagey-Sobotka; L M Lichtenstein; R M Naclerio
Journal:  Am Rev Respir Dis       Date:  1988-03

3.  Isolation of a monoclonal antibody that blocks attachment of the major group of human rhinoviruses.

Authors:  R J Colonno; P L Callahan; W J Long
Journal:  J Virol       Date:  1986-01       Impact factor: 5.103

4.  Increased levels of interleukin-1 are detected in nasal secretions of volunteers during experimental rhinovirus colds.

Authors:  D Proud; J M Gwaltney; J O Hendley; C A Dinarello; S Gillis; R P Schleimer
Journal:  J Infect Dis       Date:  1994-05       Impact factor: 5.226

5.  Therapeutic effects of an anticholinergic-sympathomimetic combination in induced rhinovirus colds.

Authors:  W J Doyle; D K Riker; T P McBride; F G Hayden; J O Hendley; J D Swarts; J M Gwaltney
Journal:  Ann Otol Rhinol Laryngol       Date:  1993-07       Impact factor: 1.547

6.  Effect of rhinovirus 39 infection on cellular immune parameters in allergic and nonallergic subjects.

Authors:  D P Skoner; T L Whiteside; J W Wilson; W J Doyle; R B Herberman; P Fireman
Journal:  J Allergy Clin Immunol       Date:  1993-11       Impact factor: 10.793

7.  Intranasally and orally administered antihistamine treatment of experimental rhinovirus colds.

Authors:  M J Gaffey; J M Gwaltney; A Sastre; W E Dressler; J V Sorrentino; F G Hayden
Journal:  Am Rev Respir Dis       Date:  1987-09

8.  Evaluation of oral terfenadine for treatment of the common cold.

Authors:  R B Berkowitz; D G Tinkelman
Journal:  Ann Allergy       Date:  1991-12

9.  Rhinovirus stimulation of interleukin-6 in vivo and in vitro. Evidence for nuclear factor kappa B-dependent transcriptional activation.

Authors:  Z Zhu; W Tang; A Ray; Y Wu; O Einarsson; M L Landry; J Gwaltney; J A Elias
Journal:  J Clin Invest       Date:  1996-01-15       Impact factor: 14.808

10.  Effects of naproxen on experimental rhinovirus colds. A randomized, double-blind, controlled trial.

Authors:  S J Sperber; J O Hendley; F G Hayden; D K Riker; J V Sorrentino; J M Gwaltney
Journal:  Ann Intern Med       Date:  1992-07-01       Impact factor: 25.391

View more
  42 in total

1.  Vaccine strategies to induce broadly protective immunity to rhinoviruses.

Authors:  Gary R McLean
Journal:  Hum Vaccin Immunother       Date:  2019-09-20       Impact factor: 3.452

Review 2.  Neural dysfunction following respiratory viral infection as a cause of chronic cough hypersensitivity.

Authors:  Bradley J Undem; Eric Zaccone; Lorcan McGarvey; Stuart B Mazzone
Journal:  Pulm Pharmacol Ther       Date:  2015-06-30       Impact factor: 3.410

Review 3.  Global airway disease beyond allergy.

Authors:  Peter W Hellings; Emmanuel P Prokopakis
Journal:  Curr Allergy Asthma Rep       Date:  2010-03       Impact factor: 4.806

4.  Efficacy of an extract of North American ginseng containing poly-furanosyl-pyranosyl-saccharides for preventing upper respiratory tract infections: a randomized controlled trial.

Authors:  Gerald N Predy; Vinti Goel; Ray Lovlin; Allan Donner; Larry Stitt; Tapan K Basu
Journal:  CMAJ       Date:  2005-10-25       Impact factor: 8.262

5.  Basal salivary cortisol secretion and susceptibility to upper respiratory infection.

Authors:  Denise Janicki-Deverts; Sheldon Cohen; Ronald B Turner; William J Doyle
Journal:  Brain Behav Immun       Date:  2016-01-14       Impact factor: 7.217

6.  Molecular diagnosis of human rhinovirus infections: comparison with virus isolation.

Authors:  T Hyypiä; T Puhakka; O Ruuskanen; M Mäkelä; A Arola; P Arstila
Journal:  J Clin Microbiol       Date:  1998-07       Impact factor: 5.948

7.  The effect of hydrotherapy on the incidence of common cold episodes in children: a randomised clinical trial.

Authors:  Christoph Grüber; Annette Riesberg; Ulrich Mansmann; Paul Knipschild; Ulrich Wahn; Malte Bühring
Journal:  Eur J Pediatr       Date:  2003-01-21       Impact factor: 3.183

8.  Validation of a short form Wisconsin Upper Respiratory Symptom Survey (WURSS-21).

Authors:  Bruce Barrett; Roger L Brown; Marlon P Mundt; Gay R Thomas; Shari K Barlow; Alex D Highstrom; Mozhdeh Bahrainian
Journal:  Health Qual Life Outcomes       Date:  2009-08-12       Impact factor: 3.186

9.  Treatment of common cold patients with the shi-cha capsule: a multicenter, double-blind, randomized, placebo-controlled, dose-escalation trial.

Authors:  Jing Chang; Shou-Jin Dong; Bin She; Rui-Ming Zhang; Mao-Bin Meng; Yan-Ling Xu; Li-Ling Wan; Ke-Hua Shi; Jun-Hun Pan; Bing Mao
Journal:  Evid Based Complement Alternat Med       Date:  2012-12-27       Impact factor: 2.629

10.  Cross-serotype immunity induced by immunization with a conserved rhinovirus capsid protein.

Authors:  Nicholas Glanville; Gary R McLean; Bruno Guy; Valerie Lecouturier; Catherine Berry; Yves Girerd; Christophe Gregoire; Ross P Walton; Rebecca M Pearson; Tatiana Kebadze; Nicolas Burdin; Nathan W Bartlett; Jeffrey W Almond; Sebastian L Johnston
Journal:  PLoS Pathog       Date:  2013-09-26       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.